Physician profile
Ennio Cenko
NPI 1508494931
$529.13
in general payments reported to CMS, 2019-2025
15 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $61.13 · 2024: $230 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509 · Debt Forgiveness: $20.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.80 |
| Debt Forgiveness | $20.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $117.99 | 2024-2025 | Veozah |
| Abbvie INC. | $82.64 | 2024-2025 | |
| Lilly USA, LLC | $50.44 | 2023-2024 | Jardiance, Trulicity, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $39.25 | 2024-2025 | Eliquis |
| Pfizer INC. | $35.49 | 2024 | |
| Novo Nordisk INC | $31.09 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Ucb, INC. | $24.72 | 2025 | Nayzilam |
| Medtronic, INC. | $24.42 | 2025 | Inceptiv |
| Merck Sharp & Dohme LLC | $22.41 | 2024 | Verquvo |
| Baxter Healthcare | $20.33 | 2024 | |
| Aimmune Therapeutics, INC. | $18.89 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.85 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $15.76 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $14.00 | 2023 | Trelegy Ellipta |
| Corcept Therapeutics | $13.85 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ennio Cenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.